Clinical Trials

    Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    Investigator: Sindhu Nair

    Study Coordinator: Misbah Baloch

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT05306340

    Phone: 713.790.3311

    Protocol Number: PRO00036451

    Description


    This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.